NEW YORK (GenomeWeb News) – Vermillion today reported flat fourth quarter revenues year over year.

For the three months ended Dec. 31, 2014, the Austin, Texas-based company recorded $1.6 million in total revenues, even with the year-ago period. Product revenues, comprised of OVA1 sales, were also flat at $1.5 million, as were licensing revenues at $113,000.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.